In sudden revamp, Celgene CEO Alles bids his COO goodbye and looks to regain confidence with management shuffle
Staggered by a series of late-stage setbacks capped by the FDA’s refusal to accept its application on their leading late-stage drug and looking vulnerable on its numbers, Celgene CEO and chairman Mark Alles is revamping the leadership structure at the wobbly biotech.
Number one on the to-do list: Scott Smith is out as president and COO, with immediate effect. He’s not retiring or off in search of new opportunities. He’s just out.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.